European CHMP recommends approval of insulin aspart biosimilar (Kixelle)

Kixelle has comparable quality, safety and efficacy to the reference product NovoRapid and is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

European Medicines Agency